Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effectiveness of a Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Relapsed Follicular Non-Hodgkin`s Lymphoma (BMT CTN #0701)

Study:

A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed Follicular Non-Hodgkin`s Lymphoma Beyond First Complete Response (BMT CTN #0701)

Rationale:

n/a

Purpose:

Blood stem cell transplants are one treatment option for people with lymphoma or other types of blood cancers. For this type of treatment, family members or unrelated donors with a similar tissue type usually donate their blood stem cells to the transplant patients. This study will evaluate the effectiveness of a type of blood stem cell transplant that uses lower doses of chemotherapy in people with relapsed follicular non-Hodgkin`s lymphoma (NHL).

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Lymphoma, Non-Hodgkin Biological: Hematopoietic Stem Cell Transplant Phase 2

Verified by National Heart, Lung, and Blood Institute (NHLBI) March, 2011

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov identifier: NCT00912223

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Mary Horowitz, MD, MS., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site